专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06201111B1 Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors 有权
标题翻译：用于治疗以肿瘤排斥抗原前体表达为特征的疾病的受试者的方法
公开(公告)号：US06201111B1
公开(公告)日：2001-03-13
申请号：US09224834
申请日：1999-01-04
申请人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wölfel , Pierre Coulie , Thierry Boon-Falleur , Etienne De Plaen
发明人： Vincent Brichard , Aline Van Pel , Catia Traversari , Thomas Wölfel , Pierre Coulie , Thierry Boon-Falleur , Etienne De Plaen
IPC分类号： C07H2102
CPC分类号： G01N33/57484 , A61K38/00 , C07K14/4748 , C07K14/70539 , Y02P20/582
摘要： The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要翻译：本发明涉及编码肿瘤排斥抗原前体的核酸分子。具体地，将肿瘤排斥抗原前体或“TRAP”加工成由HLA-A2分子呈递的至少一种肿瘤排斥抗原。还发现了这一发现的发现。

2. 发明授权

US06284476B1 Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals 失效
标题翻译：识别患有细胞异常的个体的方法，其一些异常细胞呈现人白细胞抗原/酪氨酸酶衍生肽的复合物，以及用于治疗所述个体的方法
公开(公告)号：US06284476B1
公开(公告)日：2001-09-04
申请号：US08540922
申请日：1995-10-11
申请人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wölfel , Bernard Lethé
发明人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wölfel , Bernard Lethé
IPC分类号： G01N3353
CPC分类号： G01N33/56972 , A61K38/00 , A61K39/00 , A61K48/00 , C07K14/4748 , C07K14/535 , C07K16/243 , C12N9/0071 , C12Y114/18001 , G01N33/505 , Y10S436/813 , Y10S514/885 , Y10S530/828
摘要： The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The diagnostic ramifications of this observation are the subject of the invention.
摘要翻译：本发明涉及在异常细胞表面鉴定人白细胞抗原分子和酪氨酸酶衍生肽的复合物。该观察的诊断结果是本发明的主题。

3. 发明授权

US06669946B2 METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS 有权
标题翻译：用于鉴定个体异常的方法从细胞异常中产生一些异常细胞产生人类白细胞抗原类型转移酶衍生肽的复合物，以及用于治疗上述个体的方法
公开(公告)号：US06669946B2
公开(公告)日：2003-12-30
申请号：US10011436
申请日：2001-12-11
申请人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wölfel , Bernard Lethe
发明人： Thierry Boon-Falleur , Vincent Brichard , Aline Van Pel , Etienne De Plaen , Pierre Coulie , Jean-Christope Renauld , Thomas Wölfel , Bernard Lethe
IPC分类号： A61K3900
CPC分类号： G01N33/56972 , A61K38/00 , A61K39/00 , A61K48/00 , C07K14/4748 , C07K14/535 , C07K16/243 , C12N9/0071 , C12Y114/18001 , G01N33/505 , Y10S436/813 , Y10S514/885 , Y10S530/828
摘要： The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
摘要翻译：本发明涉及异常细胞表面上的人白细胞抗原分子和酪氨酸酶衍生肽SEQ ID NO：2的复合物。该观察的治疗和诊断结果是本发明的主题。

4. 发明申请

US20100035267A1 Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients 有权
标题翻译：检测肿瘤患者肿瘤相关抗原（TAA）的个体T细胞反应模式作为个体治疗性接种疫苗的依据
公开(公告)号：US20100035267A1
公开(公告)日：2010-02-11
申请号：US12519315
申请日：2007-11-28
申请人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
发明人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： C07K14/4748 , G01N33/505 , G01N2333/70539
摘要： The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.
摘要翻译：本发明涉及用于鉴定肿瘤患者的抗肿瘤T细胞的优先靶抗原的方法，包括：a）从至少一个肿瘤患者的血液提供T细胞，b）提供树突状细胞（DC）和或所述肿瘤患者自体的B淋巴细胞（BLC），其中所述DC和BLC预先用编码T细胞免疫原性肿瘤相关抗原（TAA）的mRNA的选择进行转染，并表达这些，c）使所述T细胞与DC和/或BLC接触，d）识别识别DC和/或BLC的抗原的那些T细胞，以及e）至少鉴定所述T细胞的抗肿瘤T细胞的优先靶抗原一个肿瘤患者基于识别DC和/或BLC的抗原的T细胞。该方法还可以包括识别DC和/或BLC的抗原的T细胞的扩增。本发明还涉及一种用于产生个体化肿瘤疫苗或个体化肿瘤治疗剂的方法，以及使用个体化肿瘤疫苗或个体化肿瘤治疗剂治疗肿瘤疾病的相应方法。

5. 发明授权

US08349558B2 Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients 有权
标题翻译：在肿瘤患者中检测针对肿瘤相关抗原（TAA）的单个T细胞反应模式作为患者个体治疗性接种的基础
公开(公告)号：US08349558B2
公开(公告)日：2013-01-08
申请号：US12519315
申请日：2007-11-28
申请人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
发明人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
IPC分类号： C12N33/48 , C12N5/02 , G01N33/48 , C12N5/10
CPC分类号： C07K14/4748 , G01N33/505 , G01N2333/70539
摘要： The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.
摘要翻译：本发明涉及用于鉴定肿瘤患者的抗肿瘤T细胞的优先靶抗原的方法，包括：a）从至少一个肿瘤患者的血液提供T细胞，b）提供树突状细胞（DC）和或所述肿瘤患者自体的B淋巴细胞（BLC），其中所述DC和BLC预先用编码T细胞免疫原性肿瘤相关抗原（TAA）的mRNA的选择进行转染，并表达这些，c）使所述T细胞与DC和/或BLC接触，d）识别识别DC和/或BLC的抗原的那些T细胞，以及e）至少鉴定所述T细胞的抗肿瘤T细胞的优先靶抗原一个肿瘤患者基于识别DC和/或BLC的抗原的T细胞。该方法还可以包括识别DC和/或BLC的抗原的T细胞的扩增。本发明还涉及一种用于产生个体化肿瘤疫苗或个体化肿瘤治疗剂的方法，以及使用个体化肿瘤疫苗或个体化肿瘤治疗剂治疗肿瘤疾病的相应方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式